Progressive nodular histiocytosis
| Progressive nodular histiocytosis | |
|---|---|
| Specialty | Dermatology |
Progressive nodular histiocytosis is a cutaneous condition clinically characterized by the development of two types of skin lesions: superficial papules and deeper larger subcutaneous nodules.[1]: 718 Progressive nodular histiocytosis was first reported in 1978 by Taunton et al.[2] It is a subclass of non-Langerhans cell histiocytosis and a subgroup of xanthogranuloma.[3]
Signs and symptoms[edit]
Progressive nodular histiocytosis most frequently affects young to middle-aged adults who show up with widely distributed, randomly distributed, reddish-brown, cutaneous papules and nodules that are not painful or pruritic.[4] Progressive nodular histiocytosis's clinical course is characterized by an unwavering lack of spontaneous remission.[5] Over time, lesions grow larger and more numerous, and they can cause noticeable disfigurement.[6][3] Although mucous involvement is possible,[7] internal organs are typically unaffected.[8] Mechanical interference caused by lesions in critical locations, such as the eyelids or the soles of the feet, can result in functional impairment.[8][9] There is a rare possibility that the cutaneous lesions could cause systemic effects directly; microcytic anemia due to significant intralesional iron sequestration has been documented.[8] Obstructive lesions in the upper airway have been associated with death, despite the fact that they are usually not life-threatening.[9]
Diagnosis[edit]
Histologically, it is typified by a diffuse infiltrate of Touton giant cells and xanthomatized histiocytes mixed in with spindle-shaped histiocytes with a whorl-like growth pattern.[3]
Treatment[edit]
The primary method of treating progressive nodular histiocytosis is surgical excision.[7][8] However, a few cases have been reported to have improved following methotrexate administration.[10] Other treatments such as carbon dioxide laser, intralesional as well as systemic steroids,[8] and antineoplastic agents such as imatinib have mostly shown no effect on progressive nodular histiocytosis.[4] Unfortunately, for those who are affected, recurrence is possible even after treatment.[7]
See also[edit]
References[edit]
- ^ James, William D.; Berger, Timothy G.; et al. (2006). Andrews' Diseases of the Skin: clinical Dermatology. Saunders Elsevier. ISBN 978-0-7216-2921-6.
- ^ Taunton, O. David (1978-10-01). "Progressive Nodular Histiocytoma". Archives of Dermatology. 114 (10): 1505. doi:10.1001/archderm.1978.01640220054014. ISSN 0003-987X. PMID 214042.
- ^ a b c Chuang, Fu-Chen; Chern, Erick; Wu, Wei-Ming (2011). "Progressive nodular histiocytosis: a rare type of xanthogranuloma". Dermatologica Sinica. 29 (3). Medknow: 98–100. doi:10.1016/j.dsi.2011.07.005. ISSN 1027-8117.
- ^ a b Williams, Abhilasha; Thomas, AbrahamG; Kwatra, KanwardeepSingh; Jain, Kunal (2015). "Progressive nodular histiocytosis associated with eale′s disease". Indian Journal of Dermatology. 60 (4). Medknow: 388. doi:10.4103/0019-5154.160492. ISSN 0019-5154. PMC 4533540.
- ^ Numbere, Numbereye; Pukhalskaya, Tatsiana; Bowman, Blythe; Campbell, Katelynn; Smoller, Bruce (September 17, 2021). "Progressive Nodular Histiocytosis: Report of a Case and Review of the Literature". Case Reports in Pathology. 2021. Hindawi Limited: 1–6. doi:10.1155/2021/5531820. ISSN 2090-679X. PMC 8463211. PMID 34567817.
- ^ Kiyohara, T; Makimura, K; Miyamoto, M; Shijimaya, T; Nagano, N; Nakamaru, S; Tanimura, H (2019). "Progressive Nodular Histiocytosis with Large Nodules and a Bulky Mass". Acta Dermato Venereologica. 99 (6). Medical Journals Sweden AB: 610–611. doi:10.2340/00015555-3045. ISSN 0001-5555. PMID 30226532.
- ^ a b c Glavin, F. L.; Chhatwall, H.; Karimi, K. (October 26, 2009). "Progressive nodular histiocytosis: a case report with literature review, and discussion of differential diagnosis and classification". Journal of Cutaneous Pathology. 36 (12). Wiley: 1286–1292. doi:10.1111/j.1600-0560.2009.01454.x. ISSN 0303-6987. PMID 19878386. S2CID 22414587.
- ^ a b c d e Hilker, Olaf; Kovneristy, Alexander; Varga, Rita; Neubert, Thorsten; Wesselmann, Ulrich; Flaig, Michael J.; Ruzicka, Thomas; Burgdorf, Walter; Lehmann, Percy (December 11, 2012). "Progressive nodular histiocytosis". JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 11 (4). Wiley: 301–307. doi:10.1111/j.1610-0387.2012.08069.x. ISSN 1610-0379. PMID 23231636.
- ^ a b Salunke, Aarti; Belgaumkar, Vasudha; Chavan, Ravindranath; Dobariya, Rinkesh (2016). "Laryngeal involvement with fatal outcome in progressive nodular histiocytosis: A rare case report". Indian Dermatology Online Journal. 7 (6). Medknow: 516. doi:10.4103/2229-5178.193913. ISSN 2229-5178. PMC 5134168. PMID 27990389.
- ^ Huet, Flavien; Brenaut, Emilie; Costa, Sebastian; Lemasson, Gilles; Sonbol, Haitham; Misery, Laurent (2017). "Progressive nodular histiocytosis improved by methotrexate". European Journal of Dermatology. 27 (6). John Libbey Eurotext: 661–663. doi:10.1684/ejd.2017.3115. ISSN 1167-1122. PMID 29165296. S2CID 21473573.
Further reading[edit]
- Burgdorf, Walter H. C. (1981-10-01). "Progressive Nodular Histiocytoma". Archives of Dermatology. 117 (10): 644. doi:10.1001/archderm.1981.01650100046027. ISSN 0003-987X. PMID 6269500.
- ZELGER, B.W.H.; STAUDACHER, CH.; ORCHARD, G.; WILSON-JONES, E.; BURGDORF, W.H.C. (1995). "Solitary and generalized variants of spindle cell xanthogranuloma (progressive nodular histiocytosis)". Histopathology. 27 (1). Wiley: 11–19. doi:10.1111/j.1365-2559.1995.tb00285.x. ISSN 0309-0167. PMID 7557901. S2CID 25453049.